B+
Bull case
25%
Probability
Target price
$300.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
JAZZ
Jazz PublicBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 execution was strong, guidance was raised, and upcoming Ziihera FDA action plus HERIZON-GEA-01 data could expand the oncology growth profile. The stored median analyst target of $285.84 is above the $245.85 anchor, but target-count coverage is unavailable.
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
As of June 30, 2026, Jazz reported $4.4 billion of long-term debt versus $2.2 billion of cash, cash equivalents and investments.
Momentum
34
Value
66
Sentiment
69
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $255.00 · Bull $300.00 · Bear $210.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $292.89
Why
Momentum34 · Δ7d +7.2
Value66 · Δ7d -0.0
Sentiment69 · Δ7d +8.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +8.4.
Contradictions & invalidation
- • As of June 30, 2026, Jazz reported $4.4 billion of long-term debt versus $2.2 billion of cash, cash equivalents and investments.
- • The Actio transaction commits $820 million upfront and up to $500 million in milestones before clinical and commercial validation of ABS-1230.
- • The deterministic prior remains negative, reflecting expected near- and medium-term downside.
Catalyst clock
2026-08-25
Ziihera first-line GEA FDA decision
Lead driver: Sentiment · See AI snapshot
Momentum
34
9% active weight
Current posture
7d trendImproving
Δ7d
+7.2
Δ21d
-37.8
Value
66
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+2.3
Sentiment
69
62% active weight
Current posture
7d trendImproving
Δ7d
+8.4
Δ21d
+8.9
Why this grade
Composite grade B. Momentum 33.8 / Value 65.6 / Sentiment 69.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$255.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$210.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$16.12B
Beta
0.26
Shares Out
64.91M
P/E (TTM) · Derived
-42.5
P/S (TTM)
2.55
P/FCF (TTM)
8.55
Rev YoY
+15.5%
EPS YoY
-123.7%
Gross Margin
+73.6%
Op Margin
+20.8%
Net Debt
$2.99B
Current Ratio
1.78
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data